Eve Health Group Limited · ASX:EVE
Eve Health — Investor Presentation (November 2025)
14 slides from Eve Health's investor presentation, Nov 20, 2025
Slide 1: Smarter Innovation, Better Delivery
For personal use only SMARTER INNOVATION, BETTER DELIVERY Advancing pharmaceutical and nutraceutical delivery for better health outcomes INVESTOR LUNCH ASX: EVE © EVE HEALTH GROUP 2025
Slide 2: Executive Summary
Executive Summary For personal use only Eve Health Overview: An emerging pharmaceutical company with patent-pending, fast-acting drug delivery technology poised to disrupt the underserved women's health market, with a strong pipeline including men's health solutions. Two Innovative Products Dyspro –
Slide 3: Market Opportunity: Dysmenorrhoea and Endometriosis
Market Opportunity: Dysmenorrhoea and Endometriosis For personal use only Addressing a significant need in the women’s health market for pain relief. Existing treatments for menstrual pain and endometriosis often have slow onset, rely on hormonal therapies, and undesirable side effects. Nonsteroidal
Slide 4: Dyspro - The menstrual pain solution
TIME TO PRODUCT For personal use only EFFECTIVENESS DysproTM 5 - 15 minutes2 The menstrual pain solution NSAID Dyspro is positioned to set a new standard of care in the underserved (E.g. Ibuprofen, 30 – 60 minutes Naproxen) dysmenorrhoea and endometriosis market. Hormonal Contraceptives Several days
Slide 5: Market Opportunity: Erectile Dysfunction
For personal use only Market Opportunity: Erectile Dysfunction Addressing a significant need in the men's health market where current treatments are effective, however have slow onset, leading to high dropout rates. Phosphodiesterase 5 inhibitors (PDE5Is) are the first-line ED therapy. PDE5Is: Viagr
Slide 6: Libbo - The erectile dysfunction solution
TIME TO PRODUCT EFFECTIVENESS For personal use only Libbo 5 – 15 minutes1 (Vardenafil) Viagra 30 – 60 minutes (Sildenafil) The erectile dysfunction solution Cialis (Tadalafil) 30 – 60 minutes Libbo is positioned to transform patient experience in erectile Levitra 25 – 60 minutes dysfunction with a f
Slide 7: Product Timeline
Product Timeline Eve Health Group is moving from development to commercialisation, with Dyspro launched in For personal use only September 2025 and Libbo expected to launch in December 2025. Fast-acting, non-hormonal relief for Rapid-delivery oral strip, redefining menstrual pain and endometriosis e
Slide 8: Proprietary Technology
Proprietary Technology For personal use only Our proprietary nano-emulsion system delivers improved bioavailability, faster onset, targeted delivery, and improved stability for greater efficacy. Enhanced Solubility: Improves the solubility of existing, proven drug formulations. Improved Bioavail
Slide 9: The Patent Cliff
The Patent Cliff For personal use only Future EVE Drug Reformulation Targets Name Sale Expiry Eliquis (Apixaban) $12.2B 2026 Biktarvy (Bictegravir) $11.9B 2033 Xarelto (Rivaroxaban) $6.8B 2025 Xtandi (Enzalutamide) $6.3B 2027 Farxiga (Dapagliflozin) $6.0B 2025 Imbruvica (Ibrutinib) $4.9B 2027 Total
Slide 10: Key Milestones & News Flow, Reduced Risk Approach
Key Milestones & News Flow, Reduced Risk Approach From acquisition, formulation to product launches and export approvals, Eve Health Group is set to deliver a steady cadence For personal use only of value-driving milestones. Key Achievements Upcoming Milestones June 25 100% acquisition of new techno
Slide 11: Corporate Snapshot
Corporate Snapshot For personal use only Snapshot Ownership ASX Ticker EVE Share Price (14 Nov 2025) A$0.028 7.2% Shares on Issue 284m (83.33m escrowed until 12 June 2026) 5.8% Options on Issue Nil (23m placement options to be issued) 25.5% 4.5% Market Capitalisation (23 Sept 2025) A$8.0m Cash (Pro-
Slide 12: Important Notice and Disclaimer
For personal use only Important Notice and Disclaimer This presentation has been prepared by and issued by Eve Health Group Limited, to assist it in informing interested parties about the Company and its progress. It should not be considered as an offer or invitation to subscribe for or purchase any
Slide 13: References
For personal use only References Page 3, Market Opportunity: Dysmenorrhoea and Endometriosis 1 Prevalence and severity of dysmenorrhoea, and management options reported by young Australian women, Australian Family Physician, November 2016 2 1 in 7 Australian women aged 44–49 have endometriosis, Aust
Slide 14: For personal use only
For personal use only 1/245 Churchill Ave, Subiaco WA 6008 +61 8 6465 5500 info@evehealthgroup.com.au W W W . E V E H E A L T H G R O U P . C O M . A U S M A R T E R I N N O VAT I O N , B E T T E R D E L I V E R Y © EVE HEALTH GROUP 2025
Eve Health Group — Investor Presentation (November 2025) on 6ix